| |
Newsroom /
Health and Fitness
/
Healthcare
/
Amgen to be the Worst Hit from US Biosimilar Erosion During 2011 – 2020
Amgen to be the Worst Hit from US Biosimilar Erosion During 2011 – 2020
A new report from IMARC Group expects Amgen to lose brand sales worth US$ 8.4 Billion during 2010 and 2020 mainly as a result of biosimilar erosion.
Noida,
Uttar pardesh,
India
(prbd.net)
11/10/2011
IMARC Group, one of the world’s leading research and advisory firms, expects biopharmaceutical giant Amgen to be the worst hit from US biosimilar erosion during 2011 - 2020. According to the firm’s latest report “Biosimilar/Follow on Biologics Market Report & Forecast: A Focus on the US (2011-2020)” four products from Amgen - Enbrel (Ethanercept), Epogen (Epoetin Alpha), Neupogen (Filgrastim) and Neulasta (Pegfilgrastim) are expected to face biosimilar competition before 2020. The combined sales of these four products were US$ 12.4 Billion in 2010 and will fall to around 2.0 Billion by 2020, mainly as a result of biosimilar erosion. Biosimilars of these drugs, however, are projected to capture only US$ 3.5 Billion in sales as a result of their lower prices.
IMARC’s new report entitled “Biosimilar/Follow on Biologics Market Report & Forecast: A Focus on the US (2011-2020)” provides an analytical and statistical insight into the US biosimilar market. The study that has been undertaken using both desk-based as well as qualitative primary research has analyzed six aspects of the US biosimilar market.
Key Aspects Analyzed:
Understanding the Current Legislations on Biosimilars:
• An Insight into the Biologics Price Competition and Innovation Act
• An insight on the key biosimilar issues that still remain unaddressed
• Interchangeability and Substitutability
• Data Exclusivity
• Provisions for patent litigation
Evaluating the Current Market Landscape for Biosimilars:
• Identification of current marketed biosimilars and their historical performance
• Identifying the reasons for the slow uptake of current marketed biosimilars
• Analyzing historical data to formulate conclusions on the future growth and trends of biosimilars
Evaluating the Extent of Biosimilar Price, Sales and Volume Erosion:
• Analyzing historical time series data on price, volume and sales erosion in the US & Europe
• Analyzing previous models and assumptions on biosimilar price and volume erosion
• Evaluating and comparing biosimilar price and volume erosion with that of small molecule generics
• Evaluating and comparing biosimilar price, volume and sales erosion across various biological classes
Evaluating the Sales and Volume Erosion of Biosimilars across Various Molecules:
Molecules Covered: Somatropin, Epoitin Alfa, Filgrastim, Pegfilgrastim, Insulin Lispro, Insulin Glargin, Insulin Detemir, Interferon Beta-1A, Interferon Beta-1B, Bevacizumab, Trastuzumab, Rituximab, Cetuximab, Ethanercept, Infliximab, Adalimumab, Ranibizumab, Omalizumab and Natalizumab
Focus of the Analysis for Each Molecule:
• Historical Background and Overview
• Historical Brand Sales
• Patent Position
• Competing products
• Brand and Biosimilar Sales Forecast
Evaluating the Sales of Biosimilars across Various Indications:
Indications Covered: Immunology & Inflammation, Diabetes, Oncology, Blood Disorders and Growth Deficiency
Focus of the Analysis for Each Indication:
• Historical Brand Sales
• Brand & Biosimilar Sales Forecast
• Biosimilar Sales Forecast by Molecule
Evaluating the Biosimilar Competitive Landscape:
• Identifying branded biological manufacturers that expect the highest amount of biosimilar erosion
• Identifying biosimilar manufacturers and their pipelines
Table of Contents:
1 Market Definitions & Research Methodology
2 Executive Summary
3 The US Biosimilar Market Landscape
4 US Biosimilar Market: Current Experience
4.1 The Performance of Growth Hormone Biosimilars Has Been Dismal So Far
4.2 Pediatrics Represent the Prime Customer Base for Growth Hormones
4.3 Omnitrope Was Launched with an Inconvenient Delivery Device
4.4 Prescribing Patterns for Omnitrope
4.5 Uptake is Likely to Increase with the Accumulation of Post-Market Safety Data
5 US Biosimlar Market: How Much Price, Volume & Sales Erosion will Result
5.1 Omnitrope Cannot be Taken as a Benchmark to Gauge the Performance of Other Biosimilars
5.2 The European Uptake of ESA & GCSF Give Us a Very Positive Outlook for the US
5.3 Current & Future Biosimilar Volume Erosion Across Various Biological Classes
5.4 Current & Future Biosimilar Price Erosion Across Various Biological Classes
5.5 Current & Future Biosimilar Sales Erosion Across Various Biological Classes
6 US Biosimilar Market: Current Trends & Forecast by Drug
6.1 Growth Hormones
6.1.1 Somatropin (Genotropin/Humatrope/Other HGH)
6.2 Erythropoiesis Stimulating Agents
6.2.1 Epoetin Alfa (Epogen/Eprex)
6.3 Granulocyte Colony Stimulating Factor
6.3.1 Filgrastim (Neupogen)
6.3.2 Pegfilgrastim (Neulasta)
6.4 Insulin
6.4.1 Insulin Lispro (Humalog)
6.4.2 Insulin Glargine (Lantus)
6.4.3 Insulin Detemir (Levemir)
6.5 Interferons
6.5.1 Interferon Beta-1A (Avonex)
6.5.2 Interferon Beta-1A (Rebif)
6.5.3 Interferon Beta-1B (Betaferon/Betaseron)
6.6 TNF Alpha & Monoclonal Antibodies (Immunology & Inflammation)
6.6.1 Etanercept (Enbrel)
6.6.2 Infliximab (Remicade)
6.6.3 Adalimumab (Humira)
6.6.4 Ranibizumab (Lucentis)
6.6.5 Omalizumab (Xolair)
6.6.6 Natalizumab (Tysabri)
6.7 Monoclonal Antibodies (Oncology)
6.7.1 Bevacizumab (Avastin)
6.7.2 Trastuzumab (Herceptin)
6.7.3 Rituximab (Mabthera)
6.7.4 Cetuximab (Erbitux)
7 US Biosimilar Market: Current Trends & Forecast by Indication
7.1 Immunology & Inflammation
7.1.1 Current Trends & Forecast
7.1.2 Biosimilar Sales Breakup by Molecule
7.2 Diabetes
7.2.1 Current Trends & Forecast
7.2.2 Biosimilar Sales Breakup by Molecule
7.3 Oncology
7.3.1 Current Trends & Forecast
7.3.2 Biosimilar Sales Breakup by Molecule
7.4 Blood Disorders
7.4.1 Current Trends & Forecast
7.4.2 Biosimilar Sales Breakup by Molecule
7.5 Growth Deficiency
7.5.1 Current Trends & Forecast
7.5.2 Biosimilar Sales Breakup by Molecule
8 Competitive Landscape
8.1 Branded Manufacturers: Companies Facing the Highest Amount of Biosimilar Erosion
8.2 Biosimilar Manufacturers: Companies Gaining the Most From Biosimilar Launches
9 Biosimilar Legislation in the US
9.1 The Biologics Price Competition and Innovation Act: An Insight
9.2 Biosimlar Issues that Still Remain Unaddressed
9.3 Major Issues Impacting the Business Strategies of Biological Companies
9.3.1 Interchangeability & Substitutability
9.3.2 Data Exclusivity
9.3.3 Patent Litigation
10 Key Company Profiles
10.1 Teva
10.2 Sandoz
10.3 Hospira
10.4 Stada
10.5 Dr Reddy’s
To buy the complete report or to get a free sample:
Call: +91-120-425-6531 (Asia), +44-844-774-9660 (Europe), +1-631-791-1145 (America)
Email: sales@imarcgroup.com
For more information please visit: http://www.imarcgroup.com/biosimilarfollow-on-biologics-market-report-forecast-a-focus-on-the-us-2011-2020/
About
For more than 5 years, the International Market Analysis Research and Consulting Group has been a leading advisor on management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
Category :
Health and Fitness:Healthcare
Subscribe to
Healthcare Keywords :
US biosimilars market, Biosimilars market, Biosimilars, Amgen, Enbrel, Ethanercept, Epogen , Epoetin Alpha, Neupogen, Filgrastim, Neulasta, Pegfilgrastim
|